COVID-19 puts 1,400 out of work at Michigan Medicine

Michigan Medicine is furloughing or laying off around 1,400 fulltime employees and instituting a hiring freeze that will leave 300 current job openings unfilled.

In an internal news item, the University of Michigan-affiliated health system says the moves were necessitated by its projections of losses topping $230 million this fiscal year.

The institution names the COVID-19 crisis as the cause of the contraction, stating the sudden suspension of elective procedures and regular services had crushing financial implications.

Leadership was not spared, as signaled by CEO Marschall S. Runge’s acceptance of a 20% reduction in his own compensation and his request that department chairs and other leaders also accept pay cuts.

“While we don’t take any of these decisions lightly, we believe it is a preferable outcome to broad salary reductions and allows us to preserve as many jobs as possible,” Runge says in the news item. “The important decisions we are making at this critical juncture of the pandemic are to ensure a strong and more secure future for the health system, the medical school, and our partners and affiliates.”

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.